Citadel Advisors
ONCS

Citadel Advisors’s OncoSec Medical Incorporated ONCS Stock Holding History

Citadel Advisors’s Portfolio ONCS Stock Details ONCS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-711
Closed -$8K – 16093
2022
Q3 		$8K Sell
711
-1,686
-70% -$25.3K ﹤0.01% 12322
2022
Q2 		$39K Buy
2,397
+1,074
+81% +$20.6K ﹤0.01% 12087
2022
Q1 		$33K Sell
1,323
-510
-28% -$10.8K ﹤0.01% 13068
2021
Q4 		$39K Buy
1,833
+369
+25% +$12.5K ﹤0.01% 13389
2021
Q3 		$68K Buy
1,464
+983
+204% +$49.8K ﹤0.01% 13182
2021
Q2 		$30K Sell
481
-333
-41% -$30.2K ﹤0.01% 13484
2021
Q1 		$86K Buy
814
+224
+38% +$30.7K ﹤0.01% 12594
2020
Q4 		$84K Buy
590
+78
+15% +$8.32K ﹤0.01% 10326
2020
Q3 		$38K Sell
512
-593
-54% -$46.2K ﹤0.01% 9694
2020
Q2 		$50K Buy
+1,105
New +$47K ﹤0.01% 9311
2019
Q3 		– Sell
-594
Closed -$33K – 10195
2019
Q2 		$33K Buy
+594
New +$57.2K ﹤0.01% 8850
2019
Q1 		– Sell
-155
Closed -$22K – 10240
2018
Q4 		$22K Buy
+155
New +$38.9K ﹤0.01% 8724
2018
Q3 		– Sell
-49
Closed -$15K – 10006
2018
Q2 		$15K Buy
+49
New +$17.2K ﹤0.01% 8694
2017
Q4 		– Sell
-126
Closed -$27K – 8707
2017
Q3 		$27K Buy
126
+57
+83% +$12.7K ﹤0.01% 7313
2017
Q2 		$18K Sell
69
-53
-43% -$13K ﹤0.01% 7311
2017
Q1 		$34K Buy
+122
New +$35.5K ﹤0.01% 7145

Other funds holding ONCS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SM
Salzhauer Michael $292M AUM 30% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors's ONCS Position: Q4 2022 in Review

Citadel Advisors sold out of OncoSec Medical Incorporated (ONCS) in Q4 2022, closing a stake of 711 shares — an estimated $8K sold.

Citadel Advisors first reported a position in ONCS in Q1 2017 and held it in 16 quarters. The position peaked at $86K in Q1 2021. 17 funds tracked by Wall St. Rank hold ONCS as of Q4 2022.

  • Citadel Advisors reported no remaining OncoSec Medical Incorporated position as of Q4 2022 after selling out during the quarter.
  • Citadel Advisors sold 711 OncoSec Medical Incorporated shares in Q4 2022, an estimated $8K.
  • Citadel Advisors first reported a position in OncoSec Medical Incorporated in Q1 2017 and held it in 16 quarters.
  • Citadel Advisors's OncoSec Medical Incorporated position peaked at $86K in Q1 2021.
  • 17 funds tracked by Wall St. Rank held OncoSec Medical Incorporated as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.